Home » Newsletters » BioWorld

BioWorld

June 19, 2003

View Archived Issues

Introgen Collects $11.5M With Private Sale Of Common Stock

Introgen Therapeutics Inc. raised $11.5 million Wednesday through the private placement of 2 million common shares. (BioWorld Today) Read More

Senate Bill Addresses Medicare Reimbursement On Biologics

A Protein, RKIP, Inhibits Prostate Cancer Tumor Cells From Riding Blood Vessels To Metastatic Goal

Visit BioWorld At BIO 2003

Correction

Sunol Moves Sunol-cH36 Into Clinic; Fund-Raising In Works

Other News To Note

U.S. Patent Disclosures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...